Bevacizumab and endothelium dependent vasodilatio

Completed

Conditions: high blood pressure
Hypertension
10057166

Registration Number: NL-OMON32503

Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 24

Inclusion Criteria

1. Age 18-50 years old
2. Male
3. Results of serum glucose, lipids and creatinine should be within the laboratory's reference ranges.
4. Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.

Exclusion Criteria

1. Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.
2. History of or current abuse of drugs, alcohol or solvents.
3. History of malignant disease.
4. First degree relatives with a history of cancer before the age of 50
5. First degree relatives with a history of premature cardiovascular disease before the age of 50
6. Current use of medication.
7. Hypertension ( systole >140mmHG, diastole >90mmHg)
8. Diabetes mellitus
9. Smoking
10. Any clinically relevant abnormality on ECG.
11. A history of thrombosis or first degree family members with a history of recurrent thrombosis
12. Inability to understand the nature and extent of the trial and the procedures required.
14. Previous participation in a study with bevacizumab.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The forearm vasomotor response to increasing doses of intra-arterially<br /><br>administered acetylcholine (two doses each) before and during administration of<br /><br>bevacizumab, expressed as percentage change in forearm blood flow ratio (flow<br /><br>infused arm/flow control arm) from baseline. </p><br>

Secondary Outcome Measures